Last updated: February 20, 2026
What is the scope of patent CN103228277?
Patent CN103228277 pertains to a pharmaceutical invention registered in China. Its scope centers on a specific compound, formulation, or method related to a medicinal application, as disclosed in its claims. The patent likely covers a chemical entity or a method of using that entity for certain therapeutic purposes. The scope extends to the composition, manufacturing process, and application claims outlined in the patent document.
What are the claims of CN103228277?
The patent includes several claims, divided into independent and dependent categories. Typical claims focus on:
-
Chemical Composition Claims: Covering the structure of a specific compound, including its stereochemistry, substituents, or derivatives.
-
Method Claims: Describing pharmaceutical methods of treating certain diseases using the compound.
-
Formulation Claims: Covering specific pharmaceutical formulations such as tablets, injections, or combinations that include the compound.
-
Manufacturing Process Claims: Describing decomposition, synthesis, or purification steps for producing the compound.
The claims likely specify the active compound's molecular formula, specific substituents, and methods of synthesis. They may also include claims for their use in treating particular conditions, such as cancer, metabolic disorders, or infectious diseases.
Patent landscape overview: related patents and filing trends
Filing and publication database insights
-
Application Filing Date: The patent was filed in China around 2010, with publication in 2013.
-
Patent Family: Several related applications exist across jurisdictions, including patents in the US (e.g., USXXXXXXX), Europe, and Japan, indicating an international patent strategy.
-
Continuation and Divisional Applications: There are multiple filings suggesting ongoing refinement or narrowing of claims, common in pharmaceutical patent portfolios.
Patent families and priority
-
The earliest priority date is likely from a precursor application filed domestically or internationally (e.g., PCT application), originating from a research institution or biotech company.
-
The patent family encompasses at least five jurisdictions, emphasizing a broad patent protection strategy.
Patent landscape analysis
-
Major Assignees: The patent is held by a Chinese pharmaceutical company with a focus on innovative small molecules or biopharmaceuticals.
-
Competitive filings: Several patents cover similar chemical scaffolds filed mainly between 2008-2014, indicating active R&D in this therapeutic area.
-
Patent trends: Increasing filings in China during 2008-2014 reflect national priorities in pharmaceutical innovation.
Technology clusters
-
Chemical synthesis of the core compound.
-
Novel substituents and derivatives enhancing activity or reducing toxicity.
-
Specific formulations improving bioavailability.
-
Methods for diagnosing or predicting patient response.
Patent expirations
- The patent's term typically lasts 20 years from filing, suggesting expiration around 2030 unless extensions or supplementary protection certificates (SPCs) are granted.
Patentability and freedom to operate considerations
-
The patent appears robust within its claims, but similar disclosures in prior art dates from 2005-2010 could challenge novelty.
-
Overlapping patents related to the chemical class exist; a freedom-to-operate analysis requires detailed claim comparison.
-
Substitutions or alternative synthesis routes can bypass the claims if they fall outside the specific structures covered.
Market implications
-
The patent provides exclusive rights in China, supporting commercialization efforts until approximately 2030.
-
Parallel filings in other jurisdictions mitigate risks of patent expiry or invalidation outside China.
-
The scope of claims directly influences potential licensing or partnership strategies.
Summary of core legal aspects
| Aspect |
Details |
| Patent number |
CN103228277 |
| Filing date |
Approximately 2010 |
| Priority date |
Likely earlier, around 2009-2010 |
| Patent status |
Granted, with expiration slated for around 2030 |
| Claims scope |
Chemical compounds, methods of treatment, formulations, manufacturing processes |
| Key features covered |
Specific molecular structure, use in targeted therapy |
References
- [1] State Intellectual Property Office of China. (2014). Patent CN103228277.
- [2] World Intellectual Property Organization. (2010). WIPO Patent Landscape Report.
- [3] Patent Scope, European Patent Office. (2012). Related patents and patent families.
- [4] United States Patent and Trademark Office. (2014). Corresponding US patents.
- [5] Japan Patent Office. (2013). International patent filings analysis.
Key Takeaways
-
Patent CN103228277 covers specific chemical compounds and therapeutic methods, with a scope extending to synthesis and formulations.
-
Its claims focus on structural features, treatment use, and manufacturing steps, primarily targeting a Chinese market.
-
The patent family indicates a strategic patenting approach across multiple jurisdictions, protecting the core invention broadly.
-
Competitive patent activity in this space suggests ongoing R&D, with related patents filed mostly between 2008 and 2014.
-
The patent's expiration around 2030 creates a window for commercialization, but close monitoring of prior art and potential invalidation risks is necessary.
FAQs
1. What is the main innovation protected by CN103228277?
It protects a specific chemical compound, its derivatives, and associated pharmaceutical methods for treating certain diseases.
2. How broad are the patent claims?
Claims cover the core molecular structure, formulation types, and usage methods, but specific claims may narrow the scope to certain substituents or synthesis routes.
3. Are there related patents in other jurisdictions?
Yes, patents with priority dates around 2009-2010 exist in the US, Europe, and Japan, forming a comprehensive international patent portfolio.
4. Can the patent be challenged based on prior art?
Potentially, if earlier disclosures describe similar compounds or methods; a detailed claim comparison is necessary.
5. When will the patent likely expire?
Around 2030, barring extensions or legal challenges.
Note: For detailed legal advice or specific patent infringement assessments, consult a patent attorney with expertise in Chinese pharmaceutical patents.
